Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea
Acute Effect of Indacaterol Maleate on Static and Dynamic Lung Volume in COPD Subjects.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Enrolled patients: COPD of any disease severity in stable conditions. 48 hours of inhalatory drugs wash out.
Evaluation: Plethysmographic test, blood gas analysis, blood pressure, cardiac frequency and Borg scale evaluation in basal condition and after 60 minutes of indacaterol maleate 300 mcg inhalation.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Milano, Italy, 20138
- Pneumologia Riabilitativa - Fondazione Maugeri - Istituto Scientifico di Milano - IRCCS
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signature of consensus
- COPD diagnosis
- Age from 50 to 85 years old
- history of COPD at least of one year
- respiratory stable conditions at least of one month
- Any basal FEV1 expressed in % of predicted value
- FEV1/ Forced Vital Capacity (FVC) less than 70%
- Former or active smokers with at least a smoking history of 20 pack year
Exclusion Criteria:
- Pregnancy
- FEV1/FVC more than 70%
- Known deficit of alpha 1 antitrypsin
- Subjects submitted to a Lung Volume Reduction Surgery (LVRS)
- Subjects with known positivity to Human Immunodeficiency Virus (HIV)
- Misuse of alcool or drugs
- Absence of compliance in performing respiratory tests
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Bronchodilator
Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.
|
Dry powered, 300 mcg, only one inhalation with 24 hours duration
Other Names:
|
|
PLACEBO_COMPARATOR: Placebo
Will be administered with the same device by a third independent investigator
|
Dry powered, same to study drug, only one inhalation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intra Thoracic Gas Volume (ITGV)
Time Frame: 60 minutes after drug inhalation
|
A complete body plethysmografic test will be performed after indacaterol inhalation
|
60 minutes after drug inhalation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Forced Expired Volume in the first second (FEV1)
Time Frame: 60 minutes after drug inhalation
|
Will be performed: spirometry, Arterial blood sample, measurement of blood pressure and cardiac frequency.
All these parameters will be tested 60 minutes after inhalation of Indacaterol 300 micrograms (mcg).
|
60 minutes after drug inhalation
|
|
Partial pressure of arterial oxygen (PaO2)
Time Frame: 60 minutes after drug inhalation
|
Arterial gas analysis will be performed evaluating all arterial gases
|
60 minutes after drug inhalation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Pierachille Santus, MD, PhD, Università degli Studi di Milano-Pneumologia Riabilitativa- Fondazione Maugeri-Istituto Scientifico di Milano-IRCCS - pierachille.santus@unimi.it
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Signs and Symptoms, Respiratory
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Lung Diseases
- Tachycardia
- Hypoxia
- Dyspnea
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Maleic acid
Other Study ID Numbers
Other Study ID Numbers
- 654CEC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.